551 148

Cited 0 times in

Clinical Insights Into Novel Immune Checkpoint Inhibitors

Authors
 Jii Bum Lee  ;  Sang-Jun Ha  ;  Hye Ryun Kim 
Citation
 FRONTIERS IN PHARMACOLOGY, Vol.12 : 681320, 2021-05 
Journal Title
FRONTIERS IN PHARMACOLOGY
Issue Date
2021-05
Keywords
B7-H3 ; BTLA ; ICOS ; LAG-3 ; TIGIT ; TIM-3 ; VISTA ; immune checkpoint
Abstract
The success of immune checkpoint inhibitors (ICIs), notably anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) as well as inhibitors of CTLA-4, programmed death 1 (PD-1), and programmed death ligand-1 (PD-L1), has revolutionized treatment options for solid tumors. However, the lack of response to treatment, in terms of de novo or acquired resistance, and immune related adverse events (IRAE) remain as hurdles. One mechanisms to overcome the limitations of ICIs is to target other immune checkpoints associated with tumor microenvironment. Immune checkpoints such as lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain immunoglobulin suppressor of T cell activation (VISTA), B7 homolog 3 protein (B7-H3), inducible T cell costimulatory (ICOS), and B and T lymphocyte attenuator (BTLA) are feasible and promising options for treating solid tumors, and clinical trials are currently under active investigation. This review aims to summarize the clinical aspects of the immune checkpoints and introduce novel agents targeting these checkpoints.
Files in This Item:
T202101783.pdf Download
DOI
10.3389/fphar.2021.681320
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/183976
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links